Clinical biochemistry 07/2013; 46(16-17). DOI:10.1016/j.clinbiochem.2013.07.010 · 2.28 Impact Factor
[Show abstract] [Hide abstract]
To validate the use of a Roche serum beta-2-microglobulin (B2MG) kit for urinary B2MG measurements, and to establish reference limits for urinary B2MG/creatinine ratio from healthy individuals.
Design and methods:
The Roche B2MG Tina-Quant serum kit was used to measure urinary B2MG immunoturbidimetrically.
Using human urine as a diluent, the B2MG method was linear from 73-2156 μg/L. The imprecision on a commercially available urine QC was 4.4% at a concentration of 380 μg/L. Limit of quantification at <20% CV was 40 μg/L. Method comparison with Immulite 2000 (Siemens) yielded slope=1.180 (95% CI 1.14-1.22), intercept=11.5 (95% CI -3.6-26.6), SEE=27.6 and r=0.99 (n=26) by the Deming regression analysis. The upper reference limit of B2MG/creatinine ratio determined from 195 healthy adults was 29 μg/mmol (97.5th centile).
The serum B2MG Tina Quant reagent kit is acceptable to measure urinary B2MG.
Clinical biochemistry 07/2012; 45(16-17). DOI:10.1016/j.clinbiochem.2012.06.029 · 2.28 Impact Factor
Clinical Biochemistry 10/2008; 41(14):1265-1266. DOI:10.1016/j.clinbiochem.2008.08.010 · 2.28 Impact Factor
Available from: ifcc.org